https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Fremanezumab-Vfrm Approved by FDA for Preventative Treatment of Episodic Migraine in Children, Adolescents

Fremanezumab-Vfrm Approved by FDA for Preventative Treatment of Episodic Migraine in Children, Adolescents

The FDA approved fremanezumab for pediatric migraine prevention, offering a new treatment option for children and adolescents aged 6 to 17.

administrator

Related Articles